Monitoring recovery after CNS demyelination, a novel tool to de-risk pro-remyelinating strategies.
Xenopus
myelin
optic nerve
regeneration
visual system
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
04
04
2022
revised:
15
12
2022
accepted:
22
01
2023
medline:
2
6
2023
pubmed:
31
3
2023
entrez:
30
3
2023
Statut:
ppublish
Résumé
In multiple sclerosis, while remarkable progress has been accomplished to control the inflammatory component of the disease, repair of demyelinated lesions is still an unmet need. Despite encouraging results generated in experimental models, several candidates favouring or promoting remyelination have not reached the expected outcomes in clinical trials. One possible reason for these failures is that, in most cases, during preclinical testing, efficacy was evaluated on histology only, while functional recovery had not been assessed. We have generated a Xenopus laevis transgenic model Tg(mbp:GFP-NTR) of conditional demyelination in which spontaneous remyelination can be accelerated using candidate molecules. Xenopus laevis is a classic model for in vivo studies of myelination because tadpoles are translucent. We reasoned that demyelination should translate into loss of sensorimotor functions followed by behavioural recovery upon remyelination. To this end, we measured the swimming speed and distance travelled before and after demyelination and during the ongoing spontaneous remyelination and have developed a functional assay based on the visual avoidance of a virtual collision. Here we show that alteration of these functional and clinical performances correlated well with the level of demyelination and that histological remyelination, assayed by counting in vivo the number of myelinating oligodendrocytes in the optic nerve, translated in clinical-functional recovery. This method was further validated in tadpoles treated with pro-remyelinating agents (clemastine, siponimod) showing that increased remyelination in the optic nerve was associated with functional improvement. Our data illustrate the potential interest of correlating histopathological parameters and functional-clinical parameters to screen molecules promoting remyelination in a simple in vivo model of conditional demyelination.
Identifiants
pubmed: 36995973
pii: 7095622
doi: 10.1093/brain/awad051
pmc: PMC10232271
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2453-2463Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.
Références
Curr Opin Neurobiol. 2016 Dec;41:17-23
pubmed: 27475307
J Neurosci. 2012 Sep 12;32(37):12885-95
pubmed: 22973012
Am J Med. 2020 Dec;133(12):1380-1390.e2
pubmed: 32682869
Mult Scler. 2021 Mar;27(3):391-400
pubmed: 32507033
Cold Spring Harb Protoc. 2021 Apr 1;2021(4):
pubmed: 33272972
Lancet. 2017 Dec 2;390(10111):2481-2489
pubmed: 29029896
J Neurosci. 2003 Nov 12;23(32):10214-23
pubmed: 14614079
Res Pharm Sci. 2020 Nov 27;15(6):602-611
pubmed: 33828603
Mult Scler. 1996 Oct;2(3):125-32
pubmed: 9345376
Neuron. 2005 Jul 7;47(1):13-28
pubmed: 15996545
Brain. 2003 Apr;126(Pt 4):770-82
pubmed: 12615637
J Neurosci Methods. 2009 Aug 30;182(1):25-33
pubmed: 19481113
Eur J Pharmacol. 2015 Oct 15;765:249-57
pubmed: 26321148
Brain Pathol. 2020 Jan;30(1):137-150
pubmed: 31267597
Toxicol Lett. 2007 Mar 30;169(3):205-13
pubmed: 17317045
Mult Scler. 2018 Oct;24(11):1421-1432
pubmed: 28752787
Doc Ophthalmol. 2021 Jun;142(3):283-292
pubmed: 33381858
Mol Neurobiol. 2016 Sep;53(7):4675-84
pubmed: 26310973
Nat Rev Neurosci. 2020 Dec;21(12):682-694
pubmed: 33046886
Eur J Neurosci. 2014 Sep;40(6):2948-62
pubmed: 24995793
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4611-6
pubmed: 15557474
Brain Res Bull. 1993;32(1):57-63
pubmed: 8319104
J Vis Exp. 2019 Jan 10;(143):
pubmed: 30688311
J Cell Biol. 2008 Jun 30;181(7):1169-77
pubmed: 18573915
Brain. 2018 Jan 1;141(1):85-98
pubmed: 29244098
Brain Res. 1987 Jan 13;401(1):113-21
pubmed: 3815088
Nature. 2012 Apr 29;485(7399):517-21
pubmed: 22622581
Neurosci Biobehav Rev. 2019 Dec;107:23-46
pubmed: 31442519
Lancet Neurol. 2020 Aug;19(8):678-688
pubmed: 32702337
J Cell Biol. 1992 Nov;119(3):605-16
pubmed: 1383235
J Neuroimmunol. 2018 Jul 15;320:1-10
pubmed: 29759134
Curr Biol. 2015 Sep 21;25(18):2411-6
pubmed: 26320951
Vision Res. 2006 Mar;46(6-7):902-13
pubmed: 16242750
J Pharm Pharmacol. 1968 Apr;20(4):302-4
pubmed: 4384609
J Clin Invest. 2020 May 1;130(5):2220-2236
pubmed: 32202512
J Neurophysiol. 2009 Feb;101(2):803-15
pubmed: 19073807
Neurosci Bull. 2013 Apr;29(2):251-9
pubmed: 23558591
Nature. 2012 Jul 26;487(7408):443-8
pubmed: 22801498
Invest Ophthalmol Vis Sci. 2013 Apr 09;54(4):2582-9
pubmed: 23518774
Curr Opin Neurol. 2001 Jun;14(3):271-8
pubmed: 11371748